文献速递消化道肿瘤放疗

局部晚期直肠癌长程新辅助放化疗联合或不联合同步加量的随机II期试验

Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002).
PubMed 文献 · Radiat Oncol · 2019-11-29

FDRT-002是一项多中心随机II期试验,120例II/III期直肠癌患者随机接受50 Gy/25Fx盆腔IMRT同步卡培他滨联合奥沙利铂(A组),或50 Gy/25Fx并对原发灶同步加量5 Gy(B组)。B组ypCR率略高但差异无统计学意义(P=0.157),且切口愈合延迟更多(3 vs 13,P=0.011),局部区域控制、无病生存和总生存均无统计学差异。

要点

  • 同步加量组ypCR率略高但无统计学差异(P=0.157)。
  • 同步加量组切口愈合延迟显著增多(3 vs 13,P=0.011)。
  • 直肠系膜筋膜受累是多因素分析中生存的独立预后因素。

核心结论

  • 在奥沙利铂联合术前放化疗基础上对原发灶同步加量,ypCR率略高但导致术后切口愈合延迟。
  • 同步加量未改善局部区域控制、无病生存和总生存。
  • MRF受累对生存的影响值得进一步研究。

研究设计与样本

  • 多中心、随机、II期试验(FDRT-002,NCT01064999),2010年2月至2011年12月自3个中心入组120例II/III期直肠癌患者。
  • A组接受盆腔IMRT 50 Gy/25Fx同步卡培他滨和奥沙利铂;B组接受盆腔放疗50 Gy/25Fx并对原发灶同步加量5 Gy,CRT结束后2周接受1周期XELOX。
  • 所有患者计划CRT完成后8周接受根治性手术,无论病理结果均接受共6周期围手术期卡培他滨和奥沙利铂化疗。
  • 主要终点为病理完全缓解(ypCR)。

主要发现

  • A组和B组分别有53例和57例接受根治性手术,分别有8例和14例确认为ypCR(P=0.157)。
  • 另有10例因疾病不可切除未能接受根治性切除。
  • 两组毒性相似,B组切口愈合延迟更多(3 vs 13,P=0.011)。
  • 局部区域控制(P=0.856)、无病生存(P=0.349)和总生存(P=0.553)均无统计学差异;多因素分析显示MRF受累是生存的独立预后因素。

关键数值与推荐

  • 放疗剂量:A组盆腔IMRT 50 Gy/25Fx;B组盆腔放疗50 Gy/25Fx并对原发灶同步加量5 Gy。
  • 同步化疗为卡培他滨联合奥沙利铂,CRT后2周B组接受1周期XELOX。
  • 手术计划于CRT完成后8周进行,围手术期化疗共6周期卡培他滨和奥沙利铂。
  • ypCR:A组8例、B组14例(P=0.157);切口愈合延迟:A组3例、B组13例(P=0.011)。

临床怎么用

  • 局部晚期直肠癌术前长程放化疗中,原发灶同步加量可使ypCR率略提高,但需权衡切口愈合延迟风险。
  • 治疗决策中应关注MRF受累情况,其与生存相关。
  • 同步加量不宜作为常规推荐,需结合患者手术愈合风险个体化选择。

局限性

  • 为II期随机试验,样本量120例,统计效能有限。
  • 部分患者未接受根治性手术(10例不可切除),可能影响结局评估。
  • 随访时间及长期生存数据在摘要中未详细报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study was designed to explore whether an intensified chemoradiotherapy (CRT) led to a better clinical outcome in locally advanced rectal cancer. METHODS: Patients with stage II/III rectal cancer were randomly allocated to receive either pelvic intensity-modulated radiation therapy (IMRT) of 50 Gy/25Fx concurrently with capecitabine and oxaliplatin (Arm A), or pelvic radiation of 50 Gy/25Fx with a concomitant boost of 5 Gy to the primary lesion, followed by a cycle of XELOX 2 weeks after the end of CRT (Arm B). All patients were planned to receive a definitive operation 8 weeks after the completion of CRT and a total of six perioperative chemotherapy cycles of capecitabine and oxaliplatin regardless of pathological result. Pathological complete response (ypCR) was the primary endpoint. RESULTS: From February 2010 to December 2011, 120 patients from three centers were enrolled in this study. Ninety-five percent patients completed a full-dose chemoradiotherapy as planning. Then 53 and 57 patients received a radical surgery, and 8 and 14 cases were confirmed as ypCR in two groups (P = 0.157). The other 10 patients failed to receive a definitive resection because of unresectable disease. Similar toxicities were observed between two groups and more incision healing delay were found in Arm B (3 vs.13, P = 0.011). No statistical differences were observed in local-regional control (P = 0.856), disease-free survival (P = 0.349) and overall survival (P = 0.553). Mesorectal fascia (MRF) involvement was an independent prognostic factor for survival in multivariate analysis. CONCLUSIONS: A concomitant boost to oxalipatin-combined preoperative chemoradiotherapy demonstrated a slightly higher pCR rate but delayed incision healing after surgery. The impact of MRF involvement on survival merits further investigations. TRIAL REGISTRATION: NCT01064999 (ClinicalTrials.gov).

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wang J, Guan Y, Gu W, et al. Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002). Radiat Oncol. 2019. PMID: 31783766. doi:10.1186/s13014-019-1420-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。